Coagulation Protein Disorders clinical trials
The registry lists 21 studies for Coagulation Protein Disorders across more than 10 countries. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-10-19.
Keep track of what changes. Save the Coagulation Protein Disorders studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesStatus
Who runs them
Swedish Orphan Biovitrum (6) · BioMarin Pharmaceutical (5) · Prometic Biotherapeutics, Inc. (2) · Spark Therapeutics, Inc. (2) · University of Erlangen-Nürnberg Medical School (1) · RESCUe - RESeau Cardiologie Urgence / RESUVal - RESeau des Urgences de la vallée du Rhône (1) · Sanofi (1) · Octapharma (1)
Who these studies take
Of the 1 Coagulation Protein Disorders studies recruiting now, 0 (0%) set no upper age limit and 1 (100%) stop at 75 or younger. 1 (100%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (100%) | 1 (100%) |
| 18 | 1 (100%) | 1 (100%) |
| 30 | 0 (0%) | 0 (0%) |
| 40 | 0 (0%) | 0 (0%) |
| 50 | 0 (0%) | 0 (0%) |
| 65 | 0 (0%) | 0 (0%) |
| 75 | 0 (0%) | 0 (0%) |
| 85 | 0 (0%) | 0 (0%) |
Across all 21 studies, recruiting or not: 14% stop at 75 or younger and 14% at 65; 57% take children; 0% are for women only and 52% for men only; 10% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 21 of 21. search them.
- A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)Enrolling by invitationNCT0576838612 countries
- Treatment of Ligneous Conjunctivitis in Children With Plasminogen DeficiencyRecruitingNCT05404932Not applicable1 country
- Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog AlfaActive, not recruitingNCT06716814Phase 37 countries
- Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia ATerminatedNCT04046848Phase 1/21 country
- Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog AlfaActive, not recruitingNCT06940830Phase 48 countries
- A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in TaiwanActive, not recruitingNCT066843141 country
- Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior InhibitorsCompletedNCT04684940Phase 1/27 countries
- A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog AlfaCompletedNCT05817812Phase 314 countries
- Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia ACompletedNCT06579144Phase 14 countries
- Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia AActive, not recruitingNCT06224907Phase 31 country
- Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia ACompletedNCT04323098Phase 34 countries
- An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia BCompletedNCT039017559 countries
- Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5TerminatedNCT03520712Phase 1/24 countries
- Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor ProductsCompletedNCT029767539 countries
- Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII InhibitorsCompletedNCT03734588Phase 1/21 country
- Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A ParticipantsCompletedNCT038763014 countries
- A Study of Prometic Plasminogen IV Infusion in Subjects With HypoplasminogenemiaCompletedNCT02690714Phase 2/32 countries
- Accessibility of Prophylaxis and On-demand Treatment for Persons With Haemophilia and Other Coagulation DeficienciesStatus unknownNCT047758881 country
- Stratifying Risk for Intracerebral HaemorrhageStatus unknownNCT04140812Not applicable1 country
- Observational Study of Prophylaxis and Treatment of Acute Perioperative Bleeding With Beriplex® P/N (Probe Study)CompletedNCT010531691 country
- A Phase 1 Study of ProMetic Plasminogen (Human) Intravenous in Adults and Children With Plasminogen DeficiencyCompletedNCT02312180Phase 11 country